Explore the Potential with AI-Driven Innovation
The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.
Our high-tech, dedicated method is applied to construct targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.
Our library distinguishes itself through several key aspects:
partner
Reaxense
upacc
P02743
UPID:
SAMP_HUMAN
Alternative names:
9.5S alpha-1-glycoprotein
Alternative UPACC:
P02743
Background:
Serum amyloid P-component, also known as 9.5S alpha-1-glycoprotein, plays a crucial role in the body's immune response. It has the ability to interact with DNA and histones, scavenging nuclear material from damaged cells. Additionally, it functions as a calcium-dependent lectin, indicating its involvement in various cellular processes.
Therapeutic significance:
Understanding the role of Serum amyloid P-component could open doors to potential therapeutic strategies. Its unique ability to bind to nuclear material and function as a lectin highlights its potential as a target for drug discovery, aiming to modulate immune responses or clear damaged cellular components.